

Ceftolozane-Tazobactam (Zerbaxa®)

SALAD Contains a PENICILLIN-like structure May be appropriate in penicillin-allergic patient. Refer to CUH Antimicrobial Guidelines on Eolas for further information before administration										
Restricted Antimicrobial Please contact Microbiology/ID/Antimicrobial pharmacist for further information										
Form	Vial contains ceftolozane 1g and tazobactam 500 mg. Prescribed as combination i.e. 1g/0.5g, 2g/1g etc	Store vials at 2–8°C in fridge								
Reconstitution	Add 10mL water for injections or sodium chloride 0.9% to each 1g ceftolozane/500mg tazobactam vial and shake gently. The final volume of each vial is approximately 11.4mL Dilute further prior to administration									
Compatibility & Stability	Sodium chloride 0.9% Glucose 5%									
Administration	IV infusion <ul style="list-style-type: none"> Any required dose to 100ml infusion fluid Administer over 60 minutes <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="text-align: center;">Dose of Ceftolazone/tazobactam</th> <th style="text-align: center;">Volume of reconstituted injection</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2g/1g</td> <td style="text-align: center;">22.8ml (two vials)</td> </tr> <tr> <td style="text-align: center;">1.5g/0.75g</td> <td style="text-align: center;">17.1ml</td> </tr> <tr> <td style="text-align: center;">1g/0.5g</td> <td style="text-align: center;">11.4ml (one vial)</td> </tr> </tbody> </table>		Dose of Ceftolazone/tazobactam	Volume of reconstituted injection	2g/1g	22.8ml (two vials)	1.5g/0.75g	17.1ml	1g/0.5g	11.4ml (one vial)
Dose of Ceftolazone/tazobactam	Volume of reconstituted injection									
2g/1g	22.8ml (two vials)									
1.5g/0.75g	17.1ml									
1g/0.5g	11.4ml (one vial)									
Monitoring	Monitor: Blood pressure, heart rate. Hypersensitivity reactions including anaphylaxis, nausea, abdominal pain headache, dizziness, anxiety, fever, hypotension, tachycardia, rash, infusion site reactions, dyspnoea.									
Additional Information	Manufacturer advises ceftolozane with tazobactam may influence driving and performance of skilled tasks—increased risk of dizziness.									

Information provided relates to Zerbaxa® manufactured by Merck Sharp & Dohme

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542